TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22741052
Drug: Tamsulosin 0.4
Normalized name: tamsulosin 0.4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.4 mg orally, given 6 hours before and 6 to 12 hours after surgery
Study: 10228254
Drug: Flumazenil (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (0.1 mg/mL)
Study: 8734180
Drug: Ticlopidine 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine 0.25 g/day and aspirin 0.10 g/day for one month with low molecular weight heparin
Study: 6343750
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (preoperative gamma-therapy with doses of 4-5 Gy up to 20-25 Gy or 10 Gy up to 50 Gy)
Study: 3698850
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment alone
Study: 30240024
Drug: Methylprednisolone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (1 mL intra-articular injection)
Study: 30240024
Drug: Saline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (1 mL intra-articular injection)
Study: 27693898
Drug: Fentanyl Buccal
Normalized name: Fentanyl Buccal Film
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl Buccal Tablet (FBT)
Study: 27693898
Drug: Fentanyl Buccal
Normalized name: Fentanyl Buccal Film
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl Buccal Tablet (FBT) and Immediate-release morphine
Study: 23594026
Drug: Sandwich bone
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sandwich bone augmentation with a bovine pericardium membrane
Study: 22222005
Drug: EPO therapy
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EPO therapy (5,000 IU subcutaneously at 48 h and 72 h after IS)
Study: 14998223
Drug: Investigational oxygen-carrying
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational oxygen-carrying agents
Study: 6340977
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg loprazolam
Study: 4049902
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg loprazolam
Study: 31852704
Drug: Manualised package
Normalized name: zolmitriptan
DrugBank: Zolmitriptan (DB00315)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manualised package of interventions for TB treatment adherence
Study: 23565760
Drug: Linagliptin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linagliptin (5 mg once daily)
Study: 23565760
Drug: Metformin (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (up to 2250 mg/day)
Study: 21342151
Drug: Thiopental 2.5
Normalized name: thiopental 2.5 g intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental 2.5 mg/kg
Study: 21342151
Drug: Propofol 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 1.0 mg/kg
Study: 20467604
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g amoxicillin orally 1 hour before implant placement
Study: 17367893
Drug: 40-mg controlled-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40-mg controlled-release doxycycline once daily
Study: 15481334
Drug: Ibuprofen (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (600 mg/6 hr during 3 days)
Study: 15481334
Drug: Ibuprofen-arginate (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen-arginate (600 mg/6 hr during 3 days)
Study: 15481334
Drug: Ibuprofen-arginate
Normalized name: Heme arginate
DrugBank: Heme arginate (DB17310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen-arginate
Study: 15481334
Drug: Ibuprofen and
Normalized name: Ibuprofen and Famotidine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen and ibuprofen-arginate
Study: 11560082
Drug: Caffeine (CAF)
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine (CAF) 6 mg.kg‐1
Study: 3666158
Drug: Human alpha
Normalized name: Human alphaherpesvirus 1 Ag
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human alpha interferon 3 x 10(6) units subcutaneously daily for 1 year
Study: 21911107
Drug: Haloperidol (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (0.25 to 10 mg)
Study: 21911107
Drug: Risperidone (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (0.25 to 4 mg)
Study: 21911107
Drug: Olanzapine (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (1.25 to 20 mg)
Study: 15229466
Drug: Ritonavir (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir (300 mg twice daily for 11 days)
Study: 12681546
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment via transsylvian transinsular approach
Study: 3933262
Drug: Intramuscular opiates
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular opiates
Study: 30156361
Drug: Nebulized terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized terbutaline combined with ipratropium bromide (5 mg terbutaline + 0.5 mg IB)
Study: 30156361
Drug: Terbutaline alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline alone (5 mg)
Study: 29843509
Drug: Aprepitant (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant (80 mg) plus Palonosetron (0.075 mg)
Study: 24957552
Drug: Neo-adjuvant hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neo-adjuvant hormone therapy
Study: 21488379
Drug: Therapy based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy based on level of kidney function activity
Study: 18580346
Drug: Intravenous paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous paracetamol 1 g
Study: 18580346
Drug: 0.9% NaCl
Normalized name: Trace Metals Additive in 0.9% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCl 100 ml (placebo)
Study: 9918521
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogen (CE) 0.625 mg
Study: 7380201
Drug: Cimetidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (300 mg a.c.) added to pancreatic enzyme therapy
Study: 31233843
Drug: 100 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μg Fentanyl Sublingual Tablets (FST)
Study: 31233843
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg Subcutaneous Morphine (SCM)
Study: 28064386
Drug: Brief supportive‐expressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief supportive‐expressive therapy (SET)
Study: 26010143
Drug: GABA extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: GABA extract (200 mg GABA) with alcohol drinking (GA)
Study: 24334868
Drug: Freeze-dried strawberry
Normalized name: BLACKBERRY MESOCARP FREEZE DRIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Freeze-dried strawberry (FDS) supplementation (2 cups of FDS beverage daily for 6 weeks)
Study: 19564767
Drug: Lateral fluoroscopic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lateral fluoroscopic guidance (L guidance)
Study: 19564767
Drug: Both lateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both lateral and AP fluoroscopic guidance (AP + L guidance)
Study: 8189743
Drug: Cue exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cue exposure treatment
Study: 17076961
Drug: Standard cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard cognitive-behavioral treatment
Study: 3232784
Drug: Intra-operative crystalloid
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-operative crystalloid (1000 ml compound sodium lactate solution)
Study: 8198262
Drug: Spinal block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal block with 0.5% hyperbaric bupivacaine, 2.5 mL
Study: 8198262
Drug: Sequential combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential combined spinal-epidural block with 1.5 mL of 0.5% hyperbaric bupivacaine and additional doses if needed
Study: 28857852
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal cannula at 60 L/min
Study: 25584489
Drug: Rilotumumab (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilotumumab (7.5 and 15 mg/kg)
Study: 18090435
Drug: R-flurbiprofen 400
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: R-flurbiprofen 400 mg/d
Study: 18090435
Drug: R-flurbiprofen 800
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: R-flurbiprofen 800 mg/d
Study: 18090435
Drug: R-flurbiprofen 1600
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: R-flurbiprofen 1600 mg/d
Study: 18090435
Drug: R-flurbiprofen (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-flurbiprofen (all doses)
Study: 8290188
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg dinoprostone
Study: 8837563
Drug: Conservative therapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative therapy, n = 22 (control)
Study: 1331217
Drug: Repirinast 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repirinast 300 mg twice daily for 7 days
Study: 1331217
Drug: Cromolyn 40
Normalized name: cromolyn 40 MG/ACTUAT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cromolyn 40 mg single dose
Study: 23616624
Drug: Bortezomib consolidation
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib consolidation therapy (20 doses over 21 weeks)
Study: 23616624
Drug: Bortezomib consolidation
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib consolidation therapy
Study: 20673648
Drug: Verum remedies
Normalized name: Cinnamomum verum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verum remedies (Nux Vomica or Coffea Cruda, 30c doses)
Study: 17188782
Drug: More-aerated snack
Normalized name: polyurethane-35 (not more than MPA.S at 40 %)
Approvals — FDA: no, EMA: no, PMDA: no
Description: More-aerated snack (0.45 kcal/ml)
Study: 17188782
Drug: Less-aerated snack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less-aerated snack (1.00 kcal/ml)
Study: 9249617
Drug: Curdlan sulfate
Normalized name: curdlan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curdlan sulfate (CRDS) 50 mg/70 Kg
Study: 9249617
Drug: Curdlan sulfate
Normalized name: curdlan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curdlan sulfate (CRDS) 100 mg/70 Kg
Study: 9249617
Drug: Curdlan sulfate
Normalized name: curdlan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curdlan sulfate (CRDS) 200 mg/70 Kg
Study: 8325044
Drug: Etodolac (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etodolac (400 mg/day)
Study: 23929243
Drug: Biological therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological therapy (TNF-α inhibitors)
Study: 23929243
Drug: Targeted physiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted physiotherapy program conducted twice a week for 12 weeks
Study: 15318955
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate nasal spray (FPANS)
Study: 15318955
Drug: Placebo nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal spray (PNS)
Study: 15318955
Drug: Topical steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical steroids (FPANS)
Study: 11166493
Drug: Cortisol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol (20 mg)
Study: 8176575
Drug: Metered-dose inhaler
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered-dose inhaler with spacer (Nebuhaler)
Study: 30482701
Drug: Bivalirudin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalirudin (1 mg/kg bolus followed by 2.5 mg/kg/h infusion)
Study: 30482701
Drug: Heparin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (4 mg/kg)
Study: 31904760
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein (60 g/day)
Study: 28012280
Drug: Casein (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casein (60 g/day)
Study: 28012280
Drug: Milk fat
Normalized name: MILK FAT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk fat high in MC-SFA (63 g/day)
Study: 28012280
Drug: Milk fat
Normalized name: MILK FAT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk fat low in MC-SFA (63 g/day)
Study: 26296511
Drug: Perampanel (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perampanel (up titrated from 2 to 8 mg/d, or highest tolerated dose)
Study: 14661567
Drug: Nicorandil (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil (2 mg bolus injection 3 minutes before propofol injection, followed by continuous infusion at 6 mg.h‐1)
Study: 8720807
Drug: Furosemide suppositories
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide suppositories
Study: 8720807
Drug: Furosemide sodium
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide sodium suppositories
Study: 7427858
Drug: Adriamycin (ADR),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adriamycin (ADR), 60 mg/M2 I.V. q three weeks
Study: 7427858
Drug: Methotrexate (MTX),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (MTX), 40 mg/M2 I.V. q one week
Study: 7427858
Drug: 5-fluorouracil (5-FU),
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil (5-FU), 500 mg/m2 I.V. x 5 days q five weeks
Study: 27974712
Drug: Sofosbuvir (SOF)
Normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sofosbuvir (SOF) and Ledipasvir (LDV) therapy
Study: 17030169
Drug: VX-950 450
Normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VX-950 450 mg every 8 hours
Study: 17030169
Drug: VX-950 750
Normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VX-950 750 mg every 8 hours
Study: 17030169
Drug: VX-950 1250
Normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VX-950 1250 mg every 12 hours
Study: 17030169
Drug: VX-950 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: VX-950 (all doses)
Study: 10672977
Drug: labetalol 200
Normalized name: HCTZ 25/LABETALOL 200MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: labetalol 200 mg
Study: 7962893
Drug: Group therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group therapy (GT)
Study: 2888813
Drug: Flucloxacillin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flucloxacillin (1 mg l-1)
Study: 2888813
Drug: Tobramycin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin (2 mg l-1)
Study: 24943105
Drug: PEG 4000
Normalized name: PEG 4000
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG 4000 (8 g per day)
Study: 24943105
Drug: Lactulose (3.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose (3.3 g per day)
Study: 17617747
Drug: Ranolazine 1000
Normalized name: ranolazine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranolazine 1000 mg bid
Study: 20828645
Drug: Ranolazine 1500
Normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranolazine 1500 mg bid
Study: 10389680
Drug: Tramadol (840
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (840 mg, range: 80-1920 mg)
Study: 10389680
Drug: Morphine (238
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (238 mg, range: 20-1125 mg)
Study: 3890986
Drug: PPSB (prothrombin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPSB (prothrombin complex preparation)
Study: 26394360
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron treatment (80 mg/day for 4 weeks)
Study: 24868583
Drug: 0.12% topical
Normalized name: Luxiq 0.12% Topical Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% topical unoprostone twice daily in a randomly selected eye
Study: 20178625
Drug: Low sodium
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low sodium vegetable juice (8 or 16 fluid ounces daily)
Study: 12586793
Drug: Doxorubicin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (60 mg/m(2))
Study: 12586793
Drug: Paclitaxel (175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (175 mg/m(2)/24 h)
Study: 12586793
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of doxorubicin and paclitaxel (AT, 50 mg/m(2) and 150 mg/m(2)/24 h, plus granulocyte colony‐stimulating factor 5 mg/kg)
Study: 12586793
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of doxorubicin and paclitaxel (AT)
Study: 10028207
Drug: Weekly calendar
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly calendar reports
Study: 8694157
Drug: Tenoxicam 20
Normalized name: tenoxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam 20 mg added to prilocaine in a standard Bier's block (group 2)
Study: 7061773
Drug: High-dose group
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose group (HDG) received a mean cumulative dose of 3440 microgram cat allergen 1 (cat 1) and 10,660 microgram cat albumin (alb).
Study: 7061773
Drug: Intermediate-dose group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate-dose group (IDG) received 70 microgram cat 1 and 217 microgram alb.
Study: 7061773
Drug: Low-dose group
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose group (LDG) received 0.930 microgram cat 1 and 2.86 microgram alb.
Study: 27247174
Drug: Life Goals‐Collaborative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Life Goals‐Collaborative Care (LG‐CC)
Study: 18803940
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C 1000 mg/d
Study: 12165641
Drug: Adjuvant 5-fluorouracil-based
Normalized name: Rna-based adjuvant cv8102
DrugBank: CV-8102 (DB19184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant 5-fluorouracil-based chemotherapy
Study: 2624617
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion in potassium-depleted subjects
Study: 31559589
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D supplementation (300,000 IU for deficiency, 150,000 IU for insufficiency) administered orally 48 hours before CABG surgery
Study: 18781066
Drug: 2% starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% starch gel-like solution
Study: 18781066
Drug: 2% starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% starch and 10% sucrose solution
Study: 18781066
Drug: 2% starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% starch solution followed by 10% sucrose solution
Study: 11069341
Drug: Subcutaneous tunnelling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous tunnelling with a loop for epidural catheter fixation (n = 34)
Study: 1567042
Drug: Promethazine (0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promethazine (0.625 mg/PCA dose, average of 17.6 mg/24 h)
Study: 1567042
Drug: Control (PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (PCA with morphine only, 1.5 mg, 6-min lockout interval)
Study: 3901826
Drug: Aspirin (ASA)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (ASA) 650 mg daily postoperatively
Study: 3901826
Drug: No aspirin
Normalized name: XS No Aspirin PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: No aspirin (NASA)
Study: 30515560
Drug: SwallowIT-assisted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: SwallowIT-assisted therapy (n=26)
Study: 30515560
Drug: Clinician-directed therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinician-directed therapy (n=26)
Study: 30515560
Drug: Patient-directed therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-directed therapy (n=27)
Study: 29696707
Drug: vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: vitamin D3 (5000 IU daily) + phenylbutyrate (2 × 500 mg daily)
Study: 22524447
Drug: Cisatracurium besylate
Normalized name: Cisatracurium Besylate
DrugBank: Cisatracurium (DB00565)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisatracurium besylate therapy within 2 days of ARDS onset
Study: 18366490
Drug: Sublingual administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual administration of misoprostol (400 microg three‐hourly, up to a maximum of five doses over 24 h)
Study: 18366490
Drug: Vaginal administration
Normalized name: Antiinflammatory products for vaginal administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal administration of misoprostol (400 microg three‐hourly, up to a maximum of five doses over 24 h)
Study: 18366490
Drug: Sublingual administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual administration of misoprostol
Study: 18366490
Drug: Vaginal administration
Normalized name: Antiinflammatory products for vaginal administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal administration of misoprostol
Study: 11873073
Drug: Protease inhibitor-containing
Normalized name: Protease inhibitor-containing product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitor-containing regimen (group 2; 49 patients)
Study: 10202784
Drug: Induction chemotherapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy, allogeneic or autologous bone marrow transplantation (BMT)
Study: 7586246
Drug: Streptokinase/subcutaneous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase/subcutaneous heparin therapy
Study: 1430679
Drug: Combination thrombolytic
Normalized name: THROMBOLYTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination thrombolytic therapy
Study: 2154430
Drug: Azithromycin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (250 mg bd on day 1 and 250 mg once daily on days 2-5)
Study: 2154430
Drug: Erythromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (500 mg every 6 h for seven days)
Study: 2154430
Drug: Azithromycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (1 g single dose or 500 mg single dose on day 1 and 250 mg once daily on days 2 and 3)